• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Mersana Therapeutics

edit

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. They also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.

Recent Milestones

edit

• 
  Mersana Therapeutics received $27M in Series A funding. (7/31/12)
  Posted 7/31/12 at 7:00pm via finsmes.com
• 
  Mersana Therapeutics received $4M in Venture Round funding. (4/19/12)
  Posted 4/19/12 at 5:26pm via masshightech.com
• 
  Mersana Therapeutics received $6M in Debt funding. (4/22/11)
  Posted 4/22/11 at 5:34am via masshightech.com
• 
  Mersana Therapeutics — Appoints new CEO (9/29/10)
  Posted 9/29/10 at 8:57am via masshightech.com
• 
  Mersana Therapeutics received $21M in Venture Round funding. (11/8/05)
  Posted 7/2/10 at 3:43am via mersana.com
• 
  Mersana Therapeutics added Nicholas Bacopoulos as President & CEO.
  Posted 10/3/10 at 9:50pm

Videos

Screenshots

edit

Above: Mersana Therapeutics
Uploaded: 7/2/10

Sources

1. Mersana Therapeutics, Inc. Completes $21 Million Financing (mersana.com) [edit]
2. With cancer drug in trials, Mersana gets $6M (masshightech.com) [edit]
3. Mersana Therapeutics raises $4M (masshightech.com) [edit]
4. Mersana Therapeutics Raises $27M in Series A-1 Financing (finsmes.com) [edit]
Mersana appoints Bacopoulos to CEO post (masshightech.com) [edit]